Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response
Authors
Keywords
-
Journal
Journal of Breast Cancer
Volume 16, Issue 4, Pages 395
Publisher
Korean Breast Cancer Society (KAMJE)
Online
2014-01-11
DOI
10.4048/jbc.2013.16.4.395
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Role of Immunohistochemistry in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: An Old Tool With an Enduring Prognostic Value
- (2013) Alfonso Sánchez-Muñoz et al. Clinical Breast Cancer
- Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor–positive Breast Cancer
- (2012) Sheng Chen et al. ANNALS OF SURGICAL ONCOLOGY
- Chemotherapy and fertility
- (2012) Zeev Blumenfeld BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
- Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
- (2012) Nehmat Houssami et al. EUROPEAN JOURNAL OF CANCER
- Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy
- (2012) Changhoon Yoo et al. Journal of Breast Cancer
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
- (2011) Manfred Kaufmann et al. ANNALS OF SURGICAL ONCOLOGY
- Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
- (2011) Seung Il Kim et al. ONCOLOGY
- Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer
- (2010) T. Tanei et al. EJSO
- Neoadjuvant therapy for breast cancer
- (2010) Stephen V. Liu et al. JOURNAL OF SURGICAL ONCOLOGY
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
- (2010) Fiona M. Blows et al. PLOS MEDICINE
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
- (2009) T Hirata et al. BRITISH JOURNAL OF CANCER
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy
- (2008) Masako Kasami et al. BREAST
- Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer
- (2008) Frederique Penault-Llorca et al. HUMAN PATHOLOGY
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- (2008) Priya Rastogi et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started